OVID THERAPEUTICS INC.
441 9th Ave 14th Floor
New York, NY 10001
November 13, 2023
Via EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: | Tim Buchmiller | |
Re: | Ovid Therapeutics Inc. | |
Registration Statement on Form S-3 (File No. 333-275307) | ||
Request for Acceleration of Effective Date |
Mr. Buchmiller:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-275307) (the “Registration Statement”) to become effective on November 15, 2023, at 4:00 p.m. Eastern Time, or as soon thereafter as possible, or at such other time as its legal counsel, Cooley LLP, may request by telephone to the Staff.
Once the Registration Statement has been declared effective, please orally confirm the event with Jaime Chase of Cooley LLP, counsel to the Registrant, at (202) 728-7096 or by e-mail at jchase@cooley.com.
[Signature page follows]
Very truly yours, | ||
Ovid Therapeutics Inc. | ||
By: | /s/ Thomas M. Perone | |
Thomas M. Perone | ||
General Counsel, Corporate Secretary and Chief Compliance Officer |
cc:
Jeremy M. Levin, Ovid Therapeutics Inc.
Jeffery Rona, Ovid Therapeutics Inc.
Laura Berezin, Cooley LLP
Jaime Chase, Cooley LLP
Signature Page to Company Acceleration Request – S-3 2023